Sun Pharmaceutical Industries Ltd. April 10 announced that the Food and Drug Administration has approved its generic version of Forest Laboratories Inc.'s Namenda (memantine) 5 mg and 10 mg tablets.
Namenda is indicated for the treatment of moderate to severe Alzheimer’s disease, the Mumbai, India-based company said.
These strengths of Namenda have combined annual U.S. sales of approximately $1.2 billion, Sun Pharmaceutical Industries said.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.